60 Binney St
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
436 articles with bluebird bio
Novartis is reviewing its Sandoz division to determine the best moves to maximize value for shareholders. The strategic review will explore all options for the Swiss pharma giant.
The battle between bluebird bio and Errant Gene Therapeutics has escalated into a patent lawsuit. Errant alleges that bluebird’s gene therapies infringe on their patents for recombinant vectors.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration
bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has entered into an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
bluebird bio, Inc. announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, 2021.
8/16/2021There was plenty of clinical trial updates last week. Here’s a look.
On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation –
The hold is related to a report of a SUSAR of myelodysplastic syndrome in a patient treated with eli-cel, also known as Lenti-D, in a Phase III clinical trial.
bluebird bio, Inc. announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET.
bluebird bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 85,000 shares of common stock and 50,000 restricted stock units to a newly hired employee with a grant date of August 2, 2021.
bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.
A vaccine for herpes is under development and Rational Vaccines are going to make this a reality very soon. Here's everything you need to learn about it.
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
bluebird bio, Inc. announced that the European Commission has granted marketing authorization of SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen -matched sibling hematopoietic stem cell donor is not available.
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable.
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
bluebird bio, Inc. presented data from several studies of betibeglogene autotemcel gene therapy in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia.
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy